Dietary Amino Acids and Immunonutrition Supplementation in Cancer-Induced Skeletal Muscle Mass Depletion: A Mini-Review

Author(s): Jéssika D.P. Soares, Scott L. Howell, Filipe J. Teixeira, Gustavo D. Pimentel*

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 9 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Cancer patients display systemic inflammation, which leads to an increase in protein catabolism, thus promoting the release of free amino acids to further support metabolism and remodelling of muscle proteins. Inflammation associated with tumor growth leads to malnutrition, a factor that increases the risk of developing cachexia. With cancer-induced cachexia, nutritional interventions have gained traction as a preventative method to manage this condition. Currently, cancer consensus recommendations suggest a protein intake above 1.0 g/kg.day-1 up to 2.0 g/k.day-1 for cancer patients, although an ideal amount for some amino acids in isolation has yet to be determined. Due to controversy in the literature regarding the benefits of the biochemical mechanisms of various muscle mass supplements, such as L-leucine (including whey protein and BCAA), β-hydroxy-beta-methyl butyrate (HMβ), arginine, glutamine and creatine, several studies have carefully examined their effects. L-leucine and its derivatives appear to regulate protein synthesis by direct or indirect activation of the mTORC1 pool of kinases, further promoting muscle protein balance. Arginine and glutamine may act by reducing inflammation and infection progression, thus promoting improvements in food intake. Creatine exerts anabolic activity, acting as an immediate energy substrate to support muscle contraction further increasing lean mass, mainly due to greater water uptake by the muscle. In this narrative review, we highlighted the main findings regarding protein consumption and amino acids to mitigate cancer-induced skeletal muscle depletion.

Keywords: Cancer, sarcopenia, amino acids, protein, nutritional therapy, cancer-induced skeletal muscle depletion.

[1]
Greaves M. Cancer causation: the Darwinian downside of past success? Lancet Oncol 2002; 3(4): 244-51.
[http://dx.doi.org/10.1016/S1470-2045(02)00716-7] [PMID: 12067687]
[2]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[3]
Muscaritoli M, Anker SD, Argilés J, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr 2010; 29(2): 154-9.
[http://dx.doi.org/10.1016/j.clnu.2009.12.004] [PMID: 20060626]
[4]
Sato T, Aoyama T, Hayashi T, et al. Impact of preoperative hand grip strength on morbidity following gastric cancer surgery. Gastric Cancer 2016; 19(3): 1008-15.
[http://dx.doi.org/10.1007/s10120-015-0554-4] [PMID: 26466832]
[5]
Ryan AM, Power DG, Daly L, Cushen SJ, Ní Bhuachalla Ē, Prado CM. Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. Proc Nutr Soc 2016; 75(2): 199-211.
[http://dx.doi.org/10.1017/S002966511500419X] [PMID: 26786393]
[6]
Peters SJ, van Helvoort A, Kegler D, et al. Dose-dependent effects of leucine supplementation on preservation of muscle mass in cancer cachectic mice. Oncol Rep 2011; 26(1): 247-54.
[http://dx.doi.org/10.3892/or.2011.1269] [PMID: 21503587]
[7]
Arends J, Baracos V, Bertz H, et al. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr 2017; 36(5): 1187-96.
[http://dx.doi.org/10.1016/j.clnu.2017.06.017] [PMID: 28689670]
[8]
Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr 2017; 36(1): 11-48.
[http://dx.doi.org/10.1016/j.clnu.2016.07.015] [PMID: 27637832]
[9]
Backx EMP, Horstman AMH, Marzuca-Nassr GN, et al. Leucine supplementation does not attenuate skeletal muscle loss during leg immobilization in healthy, young men. Nutrients 2018; 10(5): 635.
[http://dx.doi.org/10.3390/nu10050635] [PMID: 29772844]
[10]
Mariette C, De Botton ML, Piessen G. Surgery in esophageal and gastric cancer patients: what is the role for nutrition support in your daily practice? Ann Surg Oncol 2012; 19(7): 2128-34.
[http://dx.doi.org/10.1245/s10434-012-2225-6] [PMID: 22322948]
[11]
Peterson SJ, Mozer M. Differentiating sarcopenia and cachexia among patients with cancer. Nutr Clin Pract 2017; 32(1): 30-9.
[http://dx.doi.org/10.1177/0884533616680354] [PMID: 28124947]
[12]
Ongaro E, Buoro V, Cinausero M, et al. Sarcopenia in gastric cancer: when the loss costs too much. Gastric Cancer 2017; 20(4): 563-72.
[http://dx.doi.org/10.1007/s10120-017-0722-9] [PMID: 28477106]
[13]
Ali SGarcia. Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options - a mini-review. Gerontology 2014; 60(4): 294-305.
[http://dx.doi.org/10.1016/j.cortex.2009.08.003] [PMID: 24731978]
[14]
Shinichiro Morishita AT and JBF. Understanding cachexia, sarcopenia, and physical exercise in patients with cancer. Intech 2016; 1: 13.
[http://dx.doi.org/10.5772/57353]
[15]
Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cachexia and sarcopenia: mechanisms and potential targets for intervention. Curr Opin Pharmacol 2015; 22: 100-6.
[http://dx.doi.org/10.1016/j.coph.2015.04.003] [PMID: 25974750]
[16]
Mendes MCS, Pimentel GD, Costa FO, Carvalheira JB. Molecular and neuroendocrine mechanisms of cancer cachexia. J Endocrinol 2015; 226(3): R29-43.
[http://dx.doi.org/10.1530/JOE-15-0170] [PMID: 26112046]
[17]
Antoun S, Raynard B. Muscle protein anabolism in advanced cancer patients: response to protein and amino acid. Ann Oncol 2018; 29(suppl. 2): pii: 10-17.
[http://dx.doi.org/10.1093/annonc/mdx809] [PMID: 29506227]
[18]
Baracos VE, Mackenzie ML. Investigations of branched-chain amino acids and their metabolites in animal models of cancer. J Nutr 2006; 136(1)(Suppl.): 237S-42S.
[http://dx.doi.org/10.1093/jn/136.1.237S] [PMID: 16365090]
[19]
Eley HL, Russell ST, Tisdale MJ. Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem J 2007; 407(1): 113-20.
[http://dx.doi.org/10.1042/BJ20070651] [PMID: 17623010]
[20]
Li F, Yin Y, Tan B, Kong X, Wu G. Leucine nutrition in animals and humans: mTOR signaling and beyond. Amino Acids 2011; 41(5): 1185-93.
[http://dx.doi.org/10.1007/s00726-011-0983-2] [PMID: 21773813]
[21]
Ham DJ, Caldow MK, Lynch GS, Koopman R. Leucine as a treatment for muscle wasting: a critical review. Clin Nutr 2014; 33(6): 937-45.
[http://dx.doi.org/10.1016/j.clnu.2014.09.016] [PMID: 25444557]
[22]
van Dijk DPJ, van de Poll MCG, Moses AGW, et al. Effects of oral meal feeding on whole body protein breakdown and protein synthesis in cachectic pancreatic cancer patients. J Cachexia Sarcopenia Muscle 2015; 6(3): 212-21.
[http://dx.doi.org/10.1002/jcsm.12029] [PMID: 26401467]
[23]
Winter A, MacAdams J, Chevalier S. Normal protein anabolic response to hyperaminoacidemia in insulin-resistant patients with lung cancer cachexia. Clin Nutr 2012; 31(5): 765-73.
[http://dx.doi.org/10.1016/j.clnu.2012.05.003] [PMID: 22647419]
[24]
Liu KA, Lashinger LM, Rasmussen AJ, Hursting SD. Leucine supplementation differentially enhances pancreatic cancer growth in lean and overweight mice. Cancer Metab 2014; 2(1): 6.
[http://dx.doi.org/10.1186/2049-3002-2-6] [PMID: 24685128]
[25]
Buse MG, Reid SS. Leucine. A possible regulator of protein turnover in muscle. J Clin Invest 1975; 56(5): 1250-61.
[http://dx.doi.org/10.1172/JCI108201] [PMID: 1237498]
[26]
van Norren K, Kegler D, Argilés JM, et al. Dietary supplementation with a specific combination of high protein, leucine, and fish oil improves muscle function and daily activity in tumour-bearing cachectic mice. Br J Cancer 2009; 100(5): 713-22.
[http://dx.doi.org/10.1038/sj.bjc.6604905] [PMID: 19259092]
[27]
Holeček M. Beta-hydroxy-beta-methylbutyrate supplementation and skeletal muscle in healthy and muscle-wasting conditions. J Cachexia Sarcopenia Muscle 2017; 8(4): 529-41.
[http://dx.doi.org/10.1002/jcsm.12208] [PMID: 28493406]
[28]
Fitschen PJ, Wilson GJ, Wilson JM, Wilund KR. Efficacy of β-hydroxy-β-methylbutyrate supplementation in elderly and clinical populations. Nutrition 2013; 29(1): 29-36.
[http://dx.doi.org/10.1016/j.nut.2012.05.005] [PMID: 23085015]
[29]
Aversa Z, Bonetto A, Costelli P, et al. ß- hydroxy-ß-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental. Cancer Cachexia 2011; 38(3): 713-20.
[30]
Aversa Z, Bonetto A, Costelli P, et al. ß- hydroxy-ß-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental Cancer Cachexia 2011; 38(3): 713-25.
[http://dx.doi.org/10.3892/ijo.2010.885] [PMID: 21184031]
[31]
Mirza KA, Pereira SL, Voss AC, Tisdale MJ. Comparison of the anticatabolic effects of leucine and Ca-β-hydroxy-β-methylbutyrate in experimental models of cancer cachexia. Nutrition 2014; 30(7-8): 807-13.
[http://dx.doi.org/10.1016/j.nut.2013.11.012] [PMID: 24984997]
[32]
Patel JJ, Miller KR, Rosenthal C, Rosenthal MD. When is it appropriate to use arginine in critical illness? Nutr Clin Pract 2016; 31(4): 438-44.
[http://dx.doi.org/10.1177/0884533616652576] [PMID: 27252277]
[33]
Buijs N, Luttikhold J, Houdijk AP, van Leeuwen PA. The role of a disturbed arginine/NO metabolism in the onset of cancer cachexia: a working hypothesis. Curr Med Chem 2012; 19(31): 5278-86.
[http://dx.doi.org/10.2174/092986712803833290] [PMID: 22963622]
[34]
Zhou M, Martindale RG. Arginine in the critical care setting. J Nutr 2007; 137(6)(Suppl. 2): 1687S-92S.
[http://dx.doi.org/10.1093/jn/137.6.1687S] [PMID: 17513448]
[35]
Reynolds JV, Thom AK, Zhang SM, Ziegler MM, Naji A, Daly JM. Arginine, protein malnutrition, and cancer. J Surg Res 1988; 45(6): 513-22.
[http://dx.doi.org/10.1016/0022-4804(88)90138-2] [PMID: 2972888]
[36]
Lacey JM, Wilmore DW. Is glutamine a conditionally essential amino acid? Nutr Rev 1990; 48(8): 297-309.
[http://dx.doi.org/10.1111/j.1753-4887.1990.tb02967.x] [PMID: 2080048]
[37]
Mori M, Smedberg M, Klaude M, et al. A tracer bolus method for investigating glutamine kinetics in humans. PLoS One 2014; 9(5)e96601
[http://dx.doi.org/10.1371/journal.pone.0096601] [PMID: 24810895]
[38]
Schlemmer M, Suchner U, Schäpers B, et al. Is glutamine deficiency the link between inflammation, malnutrition, and fatigue in cancer patients? Clin Nutr 2015; 34(6): 1258-65.
[http://dx.doi.org/10.1016/j.clnu.2014.12.021] [PMID: 25614125]
[39]
Kuhn KS, Muscaritoli M, Wischmeyer P, Stehle P. Glutamine as indispensable nutrient in oncology: experimental and clinical evidence. Eur J Nutr 2010; 49(4): 197-210.
[http://dx.doi.org/10.1007/s00394-009-0082-2] [PMID: 19936817]
[40]
Souba WW. Glutamine and cancer. Ann Surg 1993; 218(6): 715-28.
[http://dx.doi.org/10.1097/00000658-199312000-00004] [PMID: 8257221]
[41]
Yoshida S, Matsui M, Shirouzu Y, Fujita H, Yamana H. Effects of glutamine supplements and radiochemotherapy on systemic immune and gut barrier function in patients with advanced esophageal. Cancer 1998; 227(4): 485-91.
[http://dx.doi.org/10.1097/00000658-199804000-00006] [PMID: 9563534]
[42]
Martin RCG II, Agle S, Schlegel M, et al. Efficacy of preoperative immunonutrition in locally advanced pancreatic cancer undergoing irreversible electroporation (IRE). Eur J Surg Oncol 2017; 43(4): 772-9.
[http://dx.doi.org/10.1016/j.ejso.2017.01.002] [PMID: 28162818]
[43]
Campos-Ferraz PL, Gualano B, das Neves W, et al. Exploratory studies of the potential anti-cancer effects of creatine. Amino Acids 2016; 48(8): 1993-2001.
[http://dx.doi.org/10.1007/s00726-016-2180-9] [PMID: 26872655]
[44]
Gualano B, Roschel H, Lancha AH Jr, Brightbill CE, Rawson ES. In sickness and in health: the widespread application of creatine supplementation. Amino Acids 2012; 43(2): 519-29.
[http://dx.doi.org/10.1007/s00726-011-1132-7] [PMID: 22101980]
[45]
Tarnopolsky MA. Creatine as a therapeutic strategy for myopathies. Amino Acids 2011; 40(5): 1397-407.
[http://dx.doi.org/10.1007/s00726-011-0876-4] [PMID: 21399918]
[46]
Campos-Ferraz PL De, Andrade I. An overview of amines as nutritional supplements to counteract cancer cachexia. J Cachexia Sarcopenia Muscle 2014; 5(2): 105-10.
[http://dx.doi.org/10.1007/s13539-014-0138-x]
[47]
Pereira RT dos S, Dörr FA, Pinto E, et al. Can creatine supplementation form carcinogenic heterocyclic amines in humans? J Physiol 2015; 593(17): 3959-71.
[http://dx.doi.org/10.1113/JP270861] [PMID: 26148133]
[48]
Gomes-Marcondes MCC, Ventrucci G, Toledo MT, Cury L, Cooper JC. A leucine-supplemented diet improved protein content of skeletal muscle in young tumor-bearing rats. Braz J Med Biol Res 2003; 36(11): 1589-94.
[http://dx.doi.org/10.1590/S0100-879X2003001100017] [PMID: 14576914]
[49]
Ventrucci G, Mello MAR, Gomes-Marcondes MCC. Proteasome activity is altered in skeletal muscle tissue of tumour-bearing rats a leucine-rich diet. Endocr Relat Cancer 2004; 11(4): 887-95.
[http://dx.doi.org/10.1677/erc.1.00828] [PMID: 15613461]
[50]
Caperuto É́C, Tomatieli RV, Colquhoun A, Seelaender MCL, Costa Rosa LF. β-hydoxy-β-methylbutyrate supplementation affects Walker 256 tumor-bearing rats in a time-dependent manner. Clin Nutr 2007; 26(1): 117-22.
[http://dx.doi.org/10.1016/j.clnu.2006.05.007] [PMID: 17011676]
[51]
Salomão EM, Toneto AT, Silva GO, Gomes-Marcondes MCC. Physical exercise and a leucine-rich diet modulate the muscle protein metabolism in Walker tumor-bearing rats. Nutr Cancer 2010; 62(8): 1095-104.
[http://dx.doi.org/10.1080/01635581.2010.492082] [PMID: 21058197]
[52]
Cao Y, Feng Y, Zhang Y, Zhu X, Jin F. L-Arginine supplementation inhibits the growth of breast cancer by enhancing innate and adaptive immune responses mediated by suppression of MDSCs in vivo. BMC Cancer 2016; 16(343): 1-11.
[http://dx.doi.org/10.1186/s12885-016-2376-0]
[53]
Cruz B, Oliveira A, Ventrucci G, Gomes-Marcondes MCC. A leucine-rich diet modulates the mTOR cell signalling pathway in the gastrocnemius muscle under different Walker-256 tumour growth conditions. BMC Cancer 2019; 19(1): 349.
[http://dx.doi.org/10.1186/s12885-019-5448-0] [PMID: 30975087]
[54]
John A. Tayek, Bruce R. Bistrain, Dermot J. Hehir, Ramon M, Lyle L. Moldawer AGLB. Improved protein kinetics and albumin synthesis by branched chain amino acid-enriched total parenteral nutrition in cancer cachexia. Cancer 1986; 58: 147-57.
[http://dx.doi.org/10.1002/1097-0142(19860701)58:1<147:AID-CNCR2820580126>3.0.CO;2-I]
[55]
May PE, Barber A, D’Olimpio JT, Hourihane A, Abumrad NN. Reversal of cancer-related wasting using oral supplementation with a combination of β-hydroxy-β-methylbutyrate, arginine, and glutamine. Am J Surg 2002; 183(4): 471-9.
[http://dx.doi.org/10.1016/S0002-9610(02)00823-1] [PMID: 11975938]
[56]
Norman K, Stübler D, Baier P, et al. Effects of creatine supplementation on nutritional status, muscle function and quality of life in patients with colorectal cancer--a double blind randomised controlled trial. Clin Nutr 2006; 25(4): 596-605.
[http://dx.doi.org/10.1016/j.clnu.2006.01.014] [PMID: 16701923]
[57]
Azman M, Mohd Yunus MR, Sulaiman S, Syed Omar SN. Enteral glutamine supplementation in surgical patients with head and neck malignancy: A randomized controlled trial. Head Neck 2015; 37(12): 1799-807.
[http://dx.doi.org/10.1002/hed.23839] [PMID: 24992652]
[58]
Engelen MPKJ, Safar AM, Bartter T, Koeman F, Deutz NEP. High anabolic potential of essential amino acid mixtures in advanced nonsmall cell lung cancer. Ann Oncol 2015; 26(9): 1960-6.
[http://dx.doi.org/10.1093/annonc/mdv271] [PMID: 26113648]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 9
Year: 2020
Published on: 22 April, 2020
Page: [970 - 978]
Pages: 9
DOI: 10.2174/1381612826666200218100420
Price: $65

Article Metrics

PDF: 40
HTML: 8